23andMe announces CEO’s intention to pursue a potential take-private
2024年4月18日 - 9:00PM
23andMe Holding Co. (Nasdaq: ME), a leading human genetics and
biopharmaceutical company, has been made aware that Anne Wojcicki,
Chief Executive Officer, Co-Founder, and Chair of the Board of
Directors of 23andMe, is considering making a proposal to acquire
all of the outstanding shares of 23andMe that she does not
currently own, as she stated in an amendment dated April 17, 2024
to her Schedule 13D filing with the Securities and Exchange
Commission. Ms. Wojcicki currently owns shares constituting more
than 20% of the total outstanding shares and entitling her to
approximately 49% of the voting power of the total outstanding
shares of 23andMe. Ms. Wojcicki also indicated in her Schedule 13D
filing that she wishes to maintain control of 23andMe and,
therefore, will not be willing to support any alternative
transaction.
The Board of Directors of 23andMe previously
formed a Special Committee on March 28, 2024, comprised of
independent directors, to review strategic alternatives that may be
available to 23andMe to maximize shareholder value. The Special
Committee will carefully review Ms. Wojcicki’s proposal when and if
it is made available and evaluate it in light of other available
strategic alternatives, including continuing to operate as a
publicly traded company. The Special Committee is committed to
acting in the best interests of 23andMe and its shareholders.
There can be no assurance that the foregoing
will result in any particular outcome, and 23andMe does not intend
to comment further on these matters until 23andMe determines that
additional disclosure is appropriate or required by law.
The Special Committee has engaged Wells Fargo as
its financial advisor and Dechert LLP as its legal advisor.
About 23andMe23andMe is a
genetics-led consumer healthcare and biopharmaceutical company
empowering a healthier future. For more information, please visit
www.23andMe.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements, other than statements of historical fact, included
or incorporated in this press release, including statements
regarding 23andMe’s strategy, are forward-looking statements. The
words "believes," "anticipates," "estimates," "plans," "expects,"
"intends," "may," "could," "should," "potential," "likely,"
"projects," “predicts,” "continue," "will," “schedule,” and "would"
or, in each case, their negative or other variations or comparable
terminology, are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements are predictions
based on 23andMe’s current expectations and projections about
future events and various assumptions. 23andMe cannot guarantee
that it will actually achieve the plans, intentions, or
expectations disclosed in its forward-looking statements and you
should not place undue reliance on 23andMe’s forward-looking
statements. These forward-looking statements involve a number of
risks, uncertainties (many of which are beyond the control of
23andMe), or other assumptions that may cause actual results or
performance to differ materially from those expressed or implied by
these forward-looking statements. The forward-looking statements
contained herein are also subject generally to other risks and
uncertainties that are described from time to time in the Company’s
filings with the Securities and Exchange Commission, including
under Item 1A, “Risk Factors” in the Company’s most recent Annual
Report on Form 10-K, as filed with the Securities and Exchange
Commission, and as revised and updated by our Quarterly Reports on
Form 10-Q and Current Reports on Form 8-K. The statements made
herein are made as of the date of this press release and, except as
may be required by law, 23andMe undertakes no obligation to update
them, whether as a result of new information, developments, or
otherwise.
press@23andMe.com
23andMe (NASDAQ:ME)
過去 株価チャート
から 8 2024 まで 9 2024
23andMe (NASDAQ:ME)
過去 株価チャート
から 9 2023 まで 9 2024